ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted continued ...
Vertex Pharmaceuticals Incorporated today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果